Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
AVANT BIO is a Delaware limited liability company established to focus on the life sciences sector. Founded with the mission to partner with companies at the intersection of advanced technologies and novel therapeutics, AVANT BIO addresses unmet needs in therapeutic development. The firm operates with a clear vision of enhancing drug discovery and manufacturing processes through innovative investments.
Currently, AVANT BIO manages a portfolio of five notable companies, reflecting a focused investment strategy. Their active investments span across North America and Europe, showcasing geographical diversity. The firm emphasizes themes such as speed and quality in drug discovery, robust manufacturing, and clinical trial access and diversity. AVANT BIO's commitment to these areas positions it as a significant player in the life sciences investment landscape.
AVANT BIO invests in therapeutic enabling technologies, biomanufacturing tools and automation, machine learning and AI applications, healthtech, techbio, and contract services. Their thematic focus includes equitable access to therapies globally, speed and quality in drug discovery, new modalities, robust manufacturing and supply chain, clinical trial access and diversity, and innovations in healthtech. The firm seeks to enhance drug discovery and manufacturing processes through these investments.
AVANT BIO prioritizes companies that align with their mission of equitable access and innovation in drug development. They look for founders who demonstrate a commitment to addressing unmet needs in therapeutic development and who leverage advanced technologies to create impactful solutions. Their investment strategy reflects a deep understanding of the life sciences sector and the challenges it faces.
AVANT BIO's portfolio includes several notable companies that exemplify their investment strategy:
This diverse portfolio reflects AVANT BIO's commitment to investing in companies that are at the forefront of technological advancements in the life sciences sector.
Daniella Kranjac: Role not specified, but brings expertise in life sciences investments and strategic partnerships.
Sebastien Latapie: Role not specified, known for his background in technology-driven healthcare solutions.
Ole Henrik Bang-Andreasen: Role not specified, has experience in biopharmaceuticals and therapeutic development.
To pitch AVANT BIO, founders should use the contact form available on their website. It is important to include a detailed presentation that outlines the business model, market opportunity, and how the technology addresses specific challenges in the life sciences sector. Response times may vary, but founders can expect timely feedback on their submissions.
Recently, AVANT BIO has been active in the investment landscape, leading a Series B investment in Abbelight, which highlights their commitment to supporting innovative companies in the life sciences space. Additionally, they have published several blog posts, including a quarterly report and insights on significant industry deals, indicating their engagement with current trends in drug delivery and investment activities.
What are AVANT BIO's investment criteria?
AVANT BIO focuses on therapeutic enabling technologies, healthtech, and innovations in drug discovery and manufacturing. They prioritize companies that address unmet needs in therapeutic development and emphasize equitable access to therapies.
How can I pitch to AVANT BIO?
Founders can pitch their ideas through the AVANT BIO website at avant.bio. It is advisable to include a clear outline of the business model, market opportunity, and how the technology addresses specific challenges in the life sciences sector.
What makes AVANT BIO different from other investors?
AVANT BIO emphasizes equitable access to therapies and innovations in clinical trial diversity. Their thematic focus on advanced technologies such as AI and machine learning sets them apart in the life sciences investment space.
What is the geographic scope of AVANT BIO's investments?
AVANT BIO invests primarily in North America and Europe, reflecting a commitment to supporting innovative companies across these regions.
What is AVANT BIO's approach to post-investment involvement?
AVANT BIO actively engages with portfolio companies, providing support in areas such as operational guidance, strategic direction, and access to their network within the life sciences sector.
What is the typical check size for investments made by AVANT BIO?
While specific check sizes are not disclosed, AVANT BIO focuses on early-stage investments in companies that align with their thematic focus and investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.